Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITRATE: Dashboard Driven Infliximab Dosing in Acute Severe UC
NCT03937609Phase 4Terminated
- Sponsor
- University of Amsterdam
- Start
- Sep 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 4 trial of infliximab in ulcerative colitis (UC), sponsored by University of Amsterdam. Started Sep 2019; status: terminated.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03937609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937609.